CNB Bank’s Arbutus Biopharma ABUS Stock Holding History

CNB Bank’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,045	Closed	-$2K	–	379
2020 Q2	$2K	Buy	+1,045	New	+$1.71K	﹤0.01%	383

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

CNB Bank's ABUS Position: Q3 2020 in Review

CNB Bank sold out of Arbutus Biopharma (ABUS) in Q3 2020, closing a stake of 1,045 shares — an estimated $2K sold.

CNB Bank first reported a position in ABUS in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 65 funds tracked by Wall St. Rank hold ABUS as of Q3 2020.

CNB Bank reported no remaining Arbutus Biopharma position as of Q3 2020 after selling out during the quarter.
CNB Bank sold 1,045 Arbutus Biopharma shares in Q3 2020, an estimated $2K.
CNB Bank first reported a position in Arbutus Biopharma in Q2 2020 and held it in 1 quarter.
CNB Bank's Arbutus Biopharma position peaked at $2K in Q2 2020.
65 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2020.

Based on CNB Bank's 13F filing for Q3 2020, filed 26 Oct 2020.